List of Excipients in Branded Drug BROVANA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lupin Pharmaceuticals Inc	BROVANA	arformoterol tartrate	27437-055	ANHYDROUS CITRIC ACID
Lupin Pharmaceuticals Inc	BROVANA	arformoterol tartrate	27437-055	SODIUM CHLORIDE
Lupin Pharmaceuticals Inc	BROVANA	arformoterol tartrate	27437-055	TRISODIUM CITRATE DIHYDRATE
Lupin Pharmaceuticals Inc	BROVANA	arformoterol tartrate	27437-055	WATER
Lupin Pharmaceuticals Inc	BROVANA	arformoterol tartrate	27437-060	ANHYDROUS CITRIC ACID
Lupin Pharmaceuticals Inc	BROVANA	arformoterol tartrate	27437-060	SODIUM CHLORIDE
Lupin Pharmaceuticals Inc	BROVANA	arformoterol tartrate	27437-060	TRISODIUM CITRATE DIHYDRATE

Brovana Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Brovana is a preservative-free, sterile nebulizer solution containing arformoterol tartrate, the long-acting beta2-adrenergic agonist used for maintenance treatment of chronic obstructive pulmonary disease. Its excipient system is deliberately simple: sodium chloride for tonicity, citrate buffer components for pH control, and water for injection. The commercial opportunity is concentrated in generic arformoterol inhalation solution, unit-dose packaging, contract manufacturing, preservative-free respiratory products, and combination nebulized therapies rather than in novel excipient composition.

What is Brovana and how is it formulated?

Brovana is the U.S. brand name for arformoterol tartrate inhalation solution. Each 2 mL unit-dose vial contains arformoterol tartrate equivalent to 15 micrograms of arformoterol. The labeled administration schedule is one vial by nebulization twice daily, approximately 12 hours apart. Brovana is not indicated for relief of acute bronchospasm and is not a rescue medicine.[1]

Brovana formulation composition

Formulation element	Function	Commercial relevance
Arformoterol tartrate	Active pharmaceutical ingredient	Long-acting bronchodilator
Sodium chloride	Tonicity adjustment	Supports tolerability and solution osmolality
Citric acid	Acid component of buffer	Controls pH and supports chemical stability
Sodium citrate	Buffer and pH control	Stabilizes the aqueous formulation
Water for injection	Vehicle	Supports sterile inhalation delivery
Preservatives	None identified in the U.S. label	Relevant to pulmonary tolerability and packaging

The U.S. prescribing information identifies Brovana as a clear, colorless, sterile solution with a pH of approximately 5.0.[1] The formulation is supplied in a 2 mL unit-dose vial and is intended for use with a standard jet nebulizer connected to an air compressor.

The excipient strategy has three primary objectives:

1. Maintain a sterile aqueous solution suitable for inhalation.
2. Control pH and tonicity without adding unnecessary excipient burden.
3. Deliver a consistent 15 microgram dose through a nebulizer over repeated chronic use.

What excipients are used in Brovana inhalation solution?

Brovana uses a citrate-buffered isotonic formulation. Sodium chloride provides tonicity, while citric acid and sodium citrate establish the pH environment. Water for injection is the vehicle.

The formulation does not depend on suspending agents, surfactants, oils, co-solvents, or complex solubilization systems. That reduces formulation complexity and simplifies sterile filling. It also limits opportunities to differentiate a follow-on product through excipient substitution alone.

Why is the preservative-free design commercially important?

Preservative-free inhalation products have several commercial advantages:

• Lower concern about repeated pulmonary exposure to antimicrobial preservatives.
• Compatibility with chronic twice-daily administration.
• Simplified positioning for patients with airway sensitivity.
• Reduced need to demonstrate preservative tolerance in a long-term maintenance product.
• Suitability for unit-dose, single-use packaging.

The absence of preservatives shifts the manufacturing burden to sterile processing and container-closure integrity. A manufacturer cannot rely on a multidose bottle with antimicrobial protection. The commercial package must maintain sterility through the labeled use period and protect the solution from contamination before nebulization.

How does Brovana’s excipient strategy affect generic development?

Generic arformoterol inhalation solution developers must match the reference product’s critical quality attributes, not merely its active ingredient strength. For a sterile nebulized product, the relevant attributes include:

• Arformoterol identity and assay.
• Enantiomeric composition and control of unwanted stereoisomers.
• pH.
• Osmolality or tonicity.
• Delivered dose uniformity.
• Particulate matter.
• Sterility.
• Container-closure integrity.
• Solution appearance.
• Stability through labeled shelf life.
• Nebulizer performance and emitted dose.

Arformoterol is the pharmacologically active R,R-enantiomer associated with the Brovana product. Control of stereochemical purity is therefore more important than for a conventional racemic drug product. A supplier must establish reliable chiral control in the active ingredient and demonstrate that the manufacturing process does not alter the stereochemical profile.

Generic formulation opportunities

The most practical generic strategy is an excipient-matched formulation using the same general citrate, sodium chloride, and water system. This approach can reduce regulatory risk because the product is closer to the reference formulation and avoids introducing new pulmonary exposure questions.

Alternative excipient strategies may include:

• Adjusting citrate concentration while maintaining the target pH.
• Using a different buffer system, subject to compatibility and regulatory justification.
• Modifying sodium chloride concentration to achieve equivalent tonicity.
• Developing a different vial fill volume while maintaining the labeled dose.
• Improving solution stability through tighter control of oxygen exposure, light exposure, or trace metals.

The strongest commercial value is unlikely to come from a new buffer. It is more likely to come from lower manufacturing cost, improved fill-finish yield, reliable sterile supply, packaging efficiency, and broad nebulizer compatibility.

What formulations are protected by Brovana patents?

Brovana’s original exclusivity was based primarily on patents covering arformoterol and its pharmaceutical use, together with FDA regulatory exclusivity associated with the original approval. The relevant patent scope historically included the active compound, stereochemical form, therapeutic use, and pharmaceutical compositions.

The commercial importance of formulation patents is lower today than it was during the branded launch period. A generic applicant may avoid a formulation claim by using a different excipient concentration or by asserting that the relevant patent claims are invalid, unenforceable, or not infringed. A formulation patent can still create regulatory and litigation risk if it claims a narrow pH range, concentration, stability profile, or specific inhalation composition.

The current Orange Book must be used to determine whether Brovana has live listed patents, patent-use codes, or other listing information at the time of an ANDA filing. FDA’s Orange Book is the controlling public source for listed patents and exclusivity information for approved small-molecule products.[2] The Brovana label alone does not establish the current patent estate.

Patent strength assessment

Patent category	Strategic strength for Brovana
Active compound claims	Historically important, but generally vulnerable to expiration over time
Stereochemical claims	Potentially relevant if claims cover arformoterol specifically
Method-of-use claims	Can delay approval for a carved-out indication but rarely block all generic use
Formulation claims	Potentially narrow and design-around risk is significant
Nebulizer or container claims	More useful for device-specific protection than for the drug solution itself
Manufacturing claims	Can create supply-chain barriers if difficult process controls are required
Trade secrets	Potentially important for sterile filling, stability, and scale-up know-how

When did Brovana lose market exclusivity?

Brovana was approved by the FDA in 2006 under NDA 021912.[3] Its principal period of branded regulatory protection has ended, and the product competes in a genericized long-acting bronchodilator market. The exact timing of commercial generic entry depends on ANDA approvals, patent certifications, settlements, and the status of any listed patents.

The key distinction is between:

• FDA approval exclusivity, which is tied to statutory regulatory periods.
• Patent exclusivity, which depends on issued claims and expiration.
• Commercial exclusivity, which depends on actual generic supply and payer substitution.

A product can lose practical exclusivity before every conceivable patent issue has disappeared. Conversely, expired patents do not guarantee immediate generic competition if manufacturing capacity, device compatibility, or market size limits entry.

What is the FDA regulatory status of Brovana?

Brovana is an FDA-approved inhalation solution for twice-daily maintenance treatment of bronchoconstriction in patients with COPD. It is not approved as a rescue product for acute bronchospasm.[1]

The product is a sterile inhalation solution rather than a metered-dose inhaler or dry-powder inhaler. That distinction affects the regulatory pathway:

• The active ingredient is administered through a nebulizer.
• The product must meet sterile drug-product requirements.
• Device performance affects delivered dose and emitted dose.
• The generic product must demonstrate pharmaceutical equivalence and bioequivalence under the FDA’s product-specific framework.
• The applicant must control both drug formulation and container-closure performance.

For inhalation solutions, FDA product-specific guidance and ANDA requirements can make the development program more demanding than a conventional oral solid. The principal development risk is usually technical execution rather than excipient novelty.[4]

Which companies are challenging Brovana with generics?

Generic competition for arformoterol inhalation solution has emerged through ANDA-based development. The competitive set can include companies with sterile inhalation manufacturing capabilities, regional respiratory portfolios, and established relationships with hospital, long-term-care, and specialty pharmacy channels.

The relevant competitors fall into four groups:

1. Generic arformoterol inhalation solution manufacturers.
2. Manufacturers of formoterol nebulizer solution, including Perforomist-type products.
3. Manufacturers of nebulized long-acting muscarinic antagonists, including revefenacin products.
4. Suppliers of inhaled combinations and alternative nebulized COPD regimens.

The strongest entrants are likely to be companies that already manufacture sterile respiratory liquids. The barrier is higher than for tablets because the product requires validated sterile filling, low particulate levels, reliable vial sealing, and demonstrated nebulizer performance.

How does Brovana compare with competing nebulized COPD drugs?

Product	Active ingredient	Pharmacology	Typical dosing concept	Excipient opportunity
Brovana	Arformoterol	Long-acting beta2 agonist	Twice daily	Preservative-free buffered solution
Perforomist	Formoterol fumarate	Long-acting beta2 agonist	Twice daily	Similar chronic nebulized-use requirements
Yupelri	Revefenacin	Long-acting muscarinic antagonist	Once daily	Greater value in long-acting delivery and stability
Albuterol nebulizer products	Albuterol	Short-acting beta2 agonist	As needed or scheduled	High-volume generic market, lower differentiation
Nebulized budesonide products	Budesonide	Inhaled corticosteroid	Product-specific	Suspension and particle-control complexity

Brovana competes most directly with nebulized formoterol because both are long-acting beta agonists administered through a nebulizer. A commercial advantage for Brovana can arise from dose consistency, payer coverage, supply reliability, and physician familiarity rather than from a distinctive excipient profile.

What commercial opportunities exist in Brovana excipients and manufacturing?

1. Generic arformoterol unit-dose vials

The clearest opportunity is a lower-cost equivalent packaged in 2 mL sterile unit-dose vials. Value drivers include:

• Lower active ingredient cost.
• Reduced vial and carton costs.
• High-throughput aseptic filling.
• Improved yield and reduced reject rates.
• Reliable supply to long-term-care and home-health channels.

The market is particularly sensitive to manufacturing interruptions because nebulized patients depend on regular replenishment.

2. Contract development and manufacturing

A contract manufacturer with sterile liquid capability can offer formulation development, analytical method transfer, aseptic filling, packaging, and stability programs. The most valuable capabilities are:

• Low-volume precision filling.
• Unit-dose blow-fill-seal or vial systems.
• Sterility assurance.
• Extractables and leachables testing.
• Container-closure integrity testing.
• Nebulizer performance testing.
• Scale-up of citrate-buffered formulations.

3. Improved container systems

Packaging can create more defensible differentiation than excipient changes. Potential approaches include:

• Lower-cost polymer unit-dose containers.
• Improved foil overwraps for moisture and light protection.
• Easy-open packaging for patients with limited dexterity.
• Carton configurations optimized for monthly or 90-day supply.
• Tamper-evident packaging for institutional channels.
• Reduced-volume packaging for home delivery.

Any packaging change must preserve sterility, chemical stability, extractables profile, and dose delivery.

4. Combination nebulized products

Arformoterol can be commercially relevant as a component of COPD maintenance combinations. Combination development faces substantial technical challenges:

• Chemical compatibility between active ingredients.
• pH and solubility control.
• Different stability requirements.
• Dose uniformity for each active.
• Potential interaction with nebulizer materials.
• Regulatory requirements for combination products.

The commercial opportunity is strongest where the combination reduces treatment burden or provides a clear alternative to multiple separate nebulized therapies.

5. Preservative-free respiratory platform technology

The Brovana formulation illustrates a broader platform opportunity for preservative-free sterile respiratory products. A manufacturer that can reliably produce citrate-buffered, unit-dose inhalation solutions may apply the same process capabilities to:

• Bronchodilators.
• Inhaled corticosteroids.
• Mucolytics.
• Antibiotic inhalation products.
• Combination nebulizer therapies.

The platform value comes from sterile process control and packaging economics, not from the citrate system itself.

What generic entry risks exist for Brovana?

Regulatory risks

• Failure to demonstrate pharmaceutical equivalence.
• Inconsistent delivered dose through reference-compatible nebulizers.
• Sterility or particulate failures.
• Inadequate stability data.
• Differences in pH, osmolality, or container interaction.
• Uncontrolled arformoterol stereochemistry.

IP risks

• Listed formulation patents.
• Method-of-use patent claims.
• Patent-use codes affecting labeling.
• Manufacturing patents covering a process used by a contract supplier.
• Patent litigation following a Paragraph IV certification.

Commercial risks

• Low net pricing after multiple generic entrants.
• Limited physician switching because nebulizer treatment is operationally burdensome.
• Payer preference for alternative long-acting products.
• Supply-chain concentration in sterile facilities.
• Contracting pressure from group purchasing organizations and long-term-care distributors.

What Paragraph IV challenges and litigation affect Brovana?

A Paragraph IV certification is an ANDA applicant’s assertion that a listed patent is invalid, unenforceable, or not infringed. It can trigger patent litigation under the Hatch-Waxman Act and may create a 30-month stay of approval under specified conditions.[5]

The relevant Brovana litigation analysis requires current review of:

• Orange Book patent listings for NDA 021912.
• FDA patent certification records.
• Federal district court complaints.
• ANDA applicant identity.
• Patent settlement terms.
• Any 180-day generic exclusivity designation.

No commercial launch conclusion should be drawn from an ANDA filing alone. A filing can be delayed by litigation, settlement restrictions, manufacturing readiness, or FDA review.

How strong is the Brovana patent estate compared with biologic products?

Brovana is a small-molecule drug, not a biologic. It does not face biosimilar competition under the Public Health Service Act. Its competitive threat comes from generic ANDAs, not biosimilar applications.

Compared with a biologic patent estate, Brovana’s protection is more exposed to:

• Patent expiration.
• Formulation design-around.
• ANDA substitution.
• Active-ingredient sourcing.
• Multiple generic suppliers.

The primary barrier is sterile inhalation manufacturing. That barrier can slow entry, but it is less durable than a complex biologic manufacturing process or a device-integrated biologic delivery system.

What is the revenue exposure from Brovana genericization?

Revenue exposure depends on the share of branded sales that remains reimbursed without substitution, the number of approved generics, and the price discount achieved by each entrant. The largest exposure is typically concentrated in:

• Medicare and Medicaid respiratory utilization.
• Long-term-care facilities.
• Home nebulizer patients.
• Chronic COPD maintenance prescriptions.
• Institutional contracts requiring continuity of supply.

A branded manufacturer can protect residual value through authorized generic supply, contract manufacturing, patient-support services, portfolio bundling, or lifecycle products with once-daily dosing or combination therapy. Excipient reformulation alone is unlikely to preserve substantial brand pricing power unless it produces a clinically meaningful tolerability, stability, or usability benefit.

What geographic markets offer the best opportunity?

The U.S. is the most structured market for ANDA-driven competition and Orange Book analysis. Other markets may offer opportunities through national generic registration pathways, but requirements differ for:

• Inhalation-solution bioequivalence.
• Device compatibility.
• Sterility testing.
• Pharmacopoeial compliance.
• Local reference-product selection.
• Pricing and reimbursement.

Global expansion is most attractive for manufacturers that already possess regional sterile respiratory registrations and distribution relationships. The same citrate-buffered formulation may require different packaging, labeling, or stability data by jurisdiction.

Key Takeaways

• Brovana contains arformoterol tartrate in a preservative-free, citrate-buffered aqueous solution.
• The principal excipients are sodium chloride, citric acid, sodium citrate, and water for injection.
• The highest-value generic opportunity is a cost-efficient sterile 2 mL unit-dose vial.
• Excipient substitution alone offers limited differentiation because the reference formulation is simple.
• Manufacturing, sterility assurance, container-closure integrity, and nebulizer performance are the main technical barriers.
• Brovana faces generic ANDA competition rather than biosimilar competition.
• Current Orange Book listings, Paragraph IV certifications, and settlement agreements determine the live patent risk.
• Commercial opportunities include generic supply, contract manufacturing, packaging improvements, and combination nebulized products.
• Brand lifecycle protection is more likely to come from delivery convenience, combination therapy, or new dosing frequency than from a new excipient system.

FAQs

Is Brovana preservative-free?

Yes. The U.S. formulation is supplied as a sterile, preservative-free inhalation solution in single-use unit-dose vials.[1]

Can Brovana be mixed with other nebulized medicines?

The product labeling does not establish general compatibility with other nebulized drugs. Mixing should not be assumed without supporting compatibility, stability, and administration data.

What is the main excipient patent opportunity for arformoterol?

The strongest opportunity is usually process and packaging protection around sterile unit-dose delivery, not a basic citrate-buffer composition. Broad excipient claims would face substantial design-around risk.

Does Brovana have biosimilar competition?

No. Arformoterol is a small-molecule active ingredient. Competitive applications use the generic drug pathway rather than the biosimilar pathway.

What makes generic Brovana difficult to manufacture?

The main challenges are aseptic filling, low particulate control, vial sealing, stability of the buffered solution, stereochemical control of arformoterol, and consistent dose delivery through compatible nebulizers.

References

1. U.S. Food and Drug Administration. (2023). Brovana (arformoterol tartrate) inhalation solution: Prescribing information. Sunovion Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Brovana, NDA 021912. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.